Spyre Therapeutics (SYRE) Income from Continuing Operations (2015 - 2026)
Spyre Therapeutics (SYRE) posted Income from Continuing Operations of 69005000.0 for Q1 2026, down 10.36% on a QoQ basis from 62530000.0 in Q4 2025, and down 54.12% year-over-year from 150409467.16 in Q1 2025.
Spyre Therapeutics (SYRE) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Spyre Therapeutics' Income from Continuing Operations history runs 12 years deep, the most recent figure standing at 69005000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 54.12% year-over-year to 69005000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 179435000.0 (up 14.12% YoY) and the FY2025 annual result came in at 155203000.0, up 25.39% from the prior year.
- Income from Continuing Operations was 69005000.0 for Q1 2026 at Spyre Therapeutics, down from 62530000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 11183000.0 in Q3 2025 and bottomed at 217081000.0 in Q2 2023.
- A 5-year average of 50284176.47 and a median of 40107000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations plunged 872.45% — and 2025, when it surged 83.8%.
- Spyre Therapeutics' Income from Continuing Operations stood at 18822000.0 in 2022, then plunged by 235.67% to 63180000.0 in 2023, then grew by 10.9% to 56296000.0 in 2024, then dropped by 11.07% to 62530000.0 in 2025, then fell by 10.36% to 69005000.0 in 2026.
- Business Quant data shows SYRE's Income from Continuing Operations at 69005000.0 in Q1 2026, 62530000.0 in Q4 2025, and 11183000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | -69.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.01 Mn |
| Dec 31, 2025 | -62.53 Mn |
| Sep 30, 2025 | -11.18 Mn |
| Jun 30, 2025 | -36.72 Mn |
| Mar 31, 2025 | -44.77 Mn |
| Dec 31, 2024 | -56.30 Mn |
| Sep 30, 2024 | -69.03 Mn |
| Jun 30, 2024 | -38.84 Mn |
| Mar 31, 2024 | -43.86 Mn |
| Dec 31, 2023 | -63.18 Mn |
| Sep 30, 2023 | -40.11 Mn |
| Jun 30, 2023 | -217.08 Mn |
| Mar 31, 2023 | -18.42 Mn |
| Dec 31, 2022 | -18.82 Mn |
| Sep 30, 2022 | -18.23 Mn |
| Jun 30, 2022 | -22.32 Mn |
| Mar 31, 2022 | -24.44 Mn |
| Dec 31, 2021 | -20.45 Mn |
| Sep 30, 2021 | -20.31 Mn |
| Jun 30, 2021 | -6.83 Mn |